STAT3 and peripheral T-cell lymphoma, not otherwise specified: Currently, various drugs that inhibit the activity of the JAK/STAT3 pathway or SETD2-targeted drugs are in the research and development stage or clinical trials, and some have been proven to have antitumor activity against various subtypes of peripheral T-cell lymphomas (31, 32).